DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jim Cramer - 4 Bausch - 4 Jim Cramer's - 4 Jim - 4 It's - 2 Xifaxan - 2 Rafael Henrique - 2 Jeff Marks - 1
Top related locs:
U.S China — Israel BHC FL Jinan East China's Shandong province
Top related orgs:
Bausch Health - 4 Norwich Pharmaceuticals - 4 CNBC - 4 Pharmaceuticals - 3 Health - 3 Management - 3 Getty - 2 Cramer & - 1

Search resuls for: "Norwich Pharmaceuticals"


4 mentions found


☆ How previous investing mistakes are shaping my thinking on the latest stock gone wrong
  + stars: | 2024-05-05 | by ( Jim Cramer | ) www.cnbc.com   time to read: +19 min
Three times a day we would gather "off the desk," and I would have to defend every stock we owned. First, there's the obvious mistakes that we have made: Bausch Health and Foot Locker . To signify the changes, he renamed it Bausch Health in 2018, after the eye-care company Valeant bought for $8.7 billion five years earlier. We thought the IPO market would come back, and Bausch Health would win the lawsuit and all would be back on track. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.
Persons: Jeff Marks, Karen Cramer, Cramer, Karen, Max Palevsky, It's, Joseph Papa, Clint Eastwood, Papa, Jim Cramer, Valeant, Bausch, Locker, Mary Dillon, Dillon, Wall, Emerson, Cristiano Amon, Laxman Narasimhan, Howard Schultz, Narasimhan, Benckiser, Kevin Johnson, Schultz, Johnson, it's, —, Foot Locker, Jim Cramer's, Jim Organizations: Cramer &, Intel, Charitable Trust, Co, Starbucks, Bausch Health, Pharmaceuticals, Perrigo, Health, Norwich Pharmaceuticals, Former, Emerson Electric, Qualcomm, National, Eaton Corp, Broadcom, Palestine, PepsiCo, Nestle, Elliott Management, Emerson, CNBC, Getty Locations: China, —, Israel, U.S, BHC, FL, Jinan, East China's Shandong province
☆ Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
  + stars: | 2024-05-02 | by ( Jim Cramer | ) www.cnbc.com   time to read: +5 min
Bausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses — putting embattled shares under pressure. BHC YTD mountain Bausch Health YTD Bottom line Along with quarterly results, Bausch Health reaffirmed forward guidance. While not necessarily expected to see a massive increase in adoption in the future like Lilly's GLP-1s, Xifaxan currently accounts for 41% of Bausch Health sales, excluding B+L. Breaking that down: $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Bausch, Eli Lilly, It's, Xifaxan, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health, Bausch Health, Norwich Pharmaceuticals, Amneal Pharmaceuticals, Food and Drug Administration, Management, CNBC Locations: generics, Norwich
☆ Strong earnings results at Bausch Health once again overshadowed by legal battle
  + stars: | 2024-02-22 | by ( Zev Fima | ) www.cnbc.com   time to read: +4 min
Bausch Health Companies reported a fourth-quarter earnings beat on Tuesday. However , the stock's upside is likely limited until the legal battle over one of its most popular drugs is resolved. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $869 million was up 5.6% versus last year and ahead of the $863 billion consensus estimate. That makes Xifaxan responsible for 38% of Bausch Health sales, excluding B+L. Breaking that down, $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb.
Persons: we've, Bausch, Salix, companywide EBITDA, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health Companies, Pharmaceuticals, Norwich Pharmaceuticals, U.S ., Appeals, Federal Circuit, Bausch Health, Management, CNBC Locations: BLCO, Bausch
☆ Bausch Health's decent quarter can't overcome headwind of ongoing patent dispute
  + stars: | 2023-11-02 | by ( Zev Fima | ) www.cnbc.com   time to read: +4 min
But they aren't enough to overcome the headwind of the company's ongoing patent legislation. Good numbers, but they take a back seat to the legal battle over Bausch drug Xifaxan. Management didn't provide any update on timing for when the remaining 88% of BLCO that Bausch Health owns will be sold off. Management now expects companywide EBITDA in a range of $3.01 to $3.11 billion, versus an earlier range of $3.0 to $3.15 billion. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Bausch, Xifaxan, BCH's Bausch, companywide, Jim Cramer's, Jim Cramer, Jim, Timothy Fadek Organizations: Health, Revenue, Pharmaceuticals, Norwich Pharmaceuticals, D.C, Norwich, FDA, XIFAXAN, Management didn't, Bausch Health, Management, CNBC, International Pharmaceutical, Bloomberg, Getty Images Bloomberg, Getty Locations: New York, U.S, Interphex
0 next >>
Total: 4